Outsourced Pharma App Notes & Case Studies

  1. From Sequence To Scale In Seven Months 9/26/2026

    Accelerate recombinant protein development from sequence to scale while maintaining stable expression, manufacturing efficiency, and critical quality attributes.

  2. Manufacturing Glycosylated Erythropoietin Without 𝛼1,3-Fucosylation 9/26/2026

    See how expression hosts affect recombinant EPO glycosylation, bioactivity, and consistency, with reproducible N-glycan profiles and absence of α1,3-linked fucosylation.

  3. Characterization Of Fly-Derived Prolactin: Insights Into Glycosylation And Activity 9/26/2026

    Explore how D. mel-derived human prolactin (hPRL) compares with hPRL expressed in E. coli and HEK293 cells through detailed physico-chemical and biological characterization.

  4. Turning Rapid Study Start-Up Into Enrollment Momentum 9/18/2026

    A large Phase III ATTR-CM outcomes trial spanning 37 countries reached 50% enrollment eight months early, with monthly accrual rates running 3–5x above plan through coordinated cross-functional execution.

  5. Improving Accuracy In Size Measurements Of Nanomedicine 9/9/2026

    Precise particle sizing is key to formulation success. Advanced analytics overcome DLS limitations, providing reliable data that reduces risk and supports long-term product stability.

  6. Delivering API-In-Capsule For Potent, Low-Flow Compounds 9/9/2026

    See how an automated capsule-filling approach addressed poor-flow APIs, improved operator safety, and supported fast scale-up for clinical supply needs.

  7. Accelerating Technology Transfer Of A Drug Product 9/9/2026

    See how structured testing can reduce transfer risk, confirm scalability and reuse strategies, as well as how to improve process robustness and deliver meaningful savings on chemicals and consumables.

  8. Ultra Low Temperature Packaging Solutions 9/9/2026

    How do you protect advanced therapies in transit? Discover how a tailored ultra-low temperature supply chain helped maintain quality, compliance, and uninterrupted delivery.

  9. A Model To Produce CAR-T, Anywhere 9/9/2026

    Standardized point-of-care manufacturing overcomes cell therapy access, cost, and supply challenges, enabling regional centers to efficiently deliver high-quality treatments.

  10. ADCs vs. AOCs: Shared Design Principles & Key Differences In Bioconjugate Engineering 9/8/2026

    Discover how payload size, charge density, and linker dynamics shape clearance, loading ratios, and intracellular delivery in next-generation oligonucleotide bioconjugates.